Antiemetic therapy

Comprehensive Therapy

Volumn 23, Issue 8, 1997, Pages 539-545

  Axelrod, Rita S ^a  

^a TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CANNABINOID; CHOLINERGIC RECEPTOR BLOCKING AGENT; PHENOTHIAZINE DERIVATIVE; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; STEROID;

ARTICLE; DRUG COST; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; RECEPTOR BLOCKING; VOMITING;

ANTIEMETICS; DRUG THERAPY, COMBINATION; HUMANS; NAUSEA; VOMITING;

EID: 0030763795     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Costall B, Naylor RJ. Neuropharmacology of emesis in relation to clinical response. Br J Cancer. 1992;66(suppl 14):S2-S8.
2. Andrews PLR, Bhandari P. The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Semin One. 1993;29A:S11-S16.
3. Mitchell EP. Gastrointestinal toxicity of chemotherapy agents. Semin Onc. 1992;19:556-579.
4. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double blind randomized trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989;7: 108-114.
5. Gilman AG, Goodman L, Rail T, Murad F. The Pharmacologic Basis of Therapeutics. 7th ed. New York, NY: MacMillan Publishing Co.; 1985.
6. Dilly SG, Friedman D, Yocom K. Contribution of dexamethasone to antiemetic control with granisetron is greatest in patients at high risk of emesis. Proc ASCO. 1994;4:1500.
7. Gebbia V, Testa A, Valenza R, et al. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin based chemotherapy. Cancer. 1995;76:1821-1822.
8. Sallan SE, Cronin C, Zien M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer. N Engl J Med. 1980;322:135.
9. Grossman B, Lessin L, Cohen P. Droperidol prevents nausea and vomiting from cis-platinum. N Engl J Med. 1979; 301:47.
10. Peroutka SJ. Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT and 5-HT receptor agents. Pharmacol Rev. 1991;43;579-586.
11. Tyers MB. Pharmacology and preclinical antiemetic properties of ondansetron. Semin Oncol 1992;19(suppl 10):1-4.
12. Hesketh P, Navari R, Grote T, et al. Double blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol. 1996;14:2242-2249.
13. Cubeddu L, Hoffman I, Fuenmayor N. Serotonin and emesis from animals to humans: a discussion of Professor Naylor's paper. Br J Cancer. 1992;66(suppl 14XIX):S9-S11.
14. Tyers MB. Sites and mechanisms of the antiemetic action of 5-HT receptor antagonists: a discussion of Professor Naylor's paper. Br J Cancer. 1992;66 (suppl 14):12-13.
15. Cebuddu IX, Hoffman HS, Fuenmayor NT, et al. Efficacy of ondansetron (GR38032 F) and the role of serotonin in cisplatin induced nausea and vomiting. N Engl J Med. 1990; 322:810
16. Pritchard JF. Ondansetron metabolism and pharmacokinetics. Semin Onc. 1992;14(suppl 10):5-15.
17. Scarantino CW, Ornitz RD, Hoffman LG, et al. Radiation induced emesis: effects of ondansetron. Semin Oncol. 1992; 19(suppl 15):38-43.
18. Morrow GR. Behavioral factors influencing the development and expression of chemotherapy induced side effects. Br J Cancer. 1992;66(suppl 14):S54-S61.
19. Martin M. Myths and realities of antiemetic treatment. Br J Cancer. 1992;66(suppl 14):S46-S51.
20. Gandara DR, Harvey WH, Monaghan GG, et al. The delayed emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol. 1992;19 (suppl 10):67-71.
21. Kris MG, Gralla RJ, Clark R, et al. Incidence, course and severity of delayed nausea and vomiting following administration of high dose cisplatin. J Clin Oncol. 1985;3:1397-1404.
22. Kris MG, Radford JE, Pizzo BA, et al. Use of an NK 1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst. 1997;89:817-818.
23. Kris MG. Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations. Semin Oncol. 1992;19(suppl 10):61-66.
24. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin induced acute emesis. Oncology. 1994;51:113-118.